151 related articles for article (PubMed ID: 11741448)
1. Fully flexible low-mode docking: application to induced fit in HIV integrase.
Keserû GM; Kolossváry I
J Am Chem Soc; 2001 Dec; 123(50):12708-9. PubMed ID: 11741448
[No Abstract] [Full Text] [Related]
2. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.
Hazuda DJ; Felock P; Witmer M; Wolfe A; Stillmock K; Grobler JA; Espeseth A; Gabryelski L; Schleif W; Blau C; Miller MD
Science; 2000 Jan; 287(5453):646-50. PubMed ID: 10649997
[TBL] [Abstract][Full Text] [Related]
3. Induced-fit docking approach provides insight into the binding mode and mechanism of action of HIV-1 integrase inhibitors.
Barreca ML; Iraci N; De Luca L; Chimirri A
ChemMedChem; 2009 Sep; 4(9):1446-56. PubMed ID: 19544345
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trial.
Johnson AA; Marchand C; Pommier Y
Curr Top Med Chem; 2004; 4(10):1059-77. PubMed ID: 15193139
[TBL] [Abstract][Full Text] [Related]
5. Binding modes of two novel dinucleotide inhibitors of HIV-1 integrase.
Guenther S; Nair V
Bioorg Med Chem Lett; 2002 Aug; 12(16):2233-6. PubMed ID: 12127545
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of human immunodeficiency virus type 1 isolates by the integrase inhibitor L-731,988, a diketo Acid.
Reinke R; Lee DJ; Robinson WE
Antimicrob Agents Chemother; 2002 Oct; 46(10):3301-3. PubMed ID: 12234866
[TBL] [Abstract][Full Text] [Related]
7. Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors.
Chen X; Tsiang M; Yu F; Hung M; Jones GS; Zeynalzadegan A; Qi X; Jin H; Kim CU; Swaminathan S; Chen JM
J Mol Biol; 2008 Jul; 380(3):504-19. PubMed ID: 18565342
[TBL] [Abstract][Full Text] [Related]
8. New insights into the interaction between pyrrolyl diketoacids and HIV-1 integrase active site and comparison with RNase H.
Corona A; di Leva FS; Rigogliuso G; Pescatori L; Madia VN; Subra F; Delelis O; Esposito F; Cadeddu M; Costi R; Cosconati S; Novellino E; di Santo R; Tramontano E
Antiviral Res; 2016 Oct; 134():236-243. PubMed ID: 27659398
[TBL] [Abstract][Full Text] [Related]
9. Dipyrimidine-based inhibitors of HIV-1 integrase.
Neamati N
Expert Opin Investig Drugs; 2003 Feb; 12(2):289-92. PubMed ID: 12556222
[No Abstract] [Full Text] [Related]
10. Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (F185K/C280S).
Marchand C; Johnson AA; Karki RG; Pais GC; Zhang X; Cowansage K; Patel TA; Nicklaus MC; Burke TR; Pommier Y
Mol Pharmacol; 2003 Sep; 64(3):600-9. PubMed ID: 12920196
[TBL] [Abstract][Full Text] [Related]
11. Comparative docking and CoMFA analysis of curcumine derivatives as HIV-1 integrase inhibitors.
Gupta P; Garg P; Roy N
Mol Divers; 2011 Aug; 15(3):733-50. PubMed ID: 21327540
[TBL] [Abstract][Full Text] [Related]
12. Diketoacid inhibitors of HIV-1 integrase: from L-708,906 to raltegravir and beyond.
Beare KD; Coster MJ; Rutledge PJ
Curr Med Chem; 2012; 19(8):1177-92. PubMed ID: 22214459
[TBL] [Abstract][Full Text] [Related]
13. Human immunodeficiency virus type-1 integrase containing a glycine to serine mutation at position 140 is attenuated for catalysis and resistant to integrase inhibitors.
King PJ; Lee DJ; Reinke RA; Victoria JG; Beale K; Robinson WE
Virology; 2003 Feb; 306(1):147-61. PubMed ID: 12620807
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase.
Espeseth AS; Felock P; Wolfe A; Witmer M; Grobler J; Anthony N; Egbertson M; Melamed JY; Young S; Hamill T; Cole JL; Hazuda DJ
Proc Natl Acad Sci U S A; 2000 Oct; 97(21):11244-9. PubMed ID: 11016953
[TBL] [Abstract][Full Text] [Related]
15. New chloro,fluorobenzylindole derivatives as integrase strand-transfer inhibitors (INSTIs) and their mode of action.
Ferro S; De Luca L; Barreca ML; De Grazia S; Christ F; Debyser Z; Chimirri A
Bioorg Med Chem; 2010 Aug; 18(15):5510-8. PubMed ID: 20630765
[TBL] [Abstract][Full Text] [Related]
16. Design and optimization of tricyclic phtalimide analogues as novel inhibitors of HIV-1 integrase.
Verschueren WG; Dierynck I; Amssoms KI; Hu L; Boonants PM; Pille GM; Daeyaert FF; Hertogs K; Surleraux DL; Wigerinck PB
J Med Chem; 2005 Mar; 48(6):1930-40. PubMed ID: 15771437
[TBL] [Abstract][Full Text] [Related]
17. Identification of a small-molecule binding site at the dimer interface of the HIV integrase catalytic domain.
Molteni V; Greenwald J; Rhodes D; Hwang Y; Kwiatkowski W; Bushman FD; Siegel JS; Choe S
Acta Crystallogr D Biol Crystallogr; 2001 Apr; 57(Pt 4):536-44. PubMed ID: 11264582
[TBL] [Abstract][Full Text] [Related]
18. Biotinylated biphenyl ketone-containing 2,4-dioxobutanoic acids designed as HIV-1 integrase photoaffinity ligands.
Zhao XZ; Semenova EA; Liao C; Nicklaus M; Pommier Y; Burke TR
Bioorg Med Chem; 2006 Dec; 14(23):7816-25. PubMed ID: 16908168
[TBL] [Abstract][Full Text] [Related]
19. Targeting HIV-1 integrase with strand transfer inhibitors.
Li Y; Xuan S; Feng Y; Yan A
Drug Discov Today; 2015 Apr; 20(4):435-49. PubMed ID: 25486307
[TBL] [Abstract][Full Text] [Related]
20. Docking-based 3D-QSAR study of HIV-1 integrase inhibitors.
Gupta P; Roy N; Garg P
Eur J Med Chem; 2009 Nov; 44(11):4276-87. PubMed ID: 19647906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
